May Jody C, Zlibut Emanuel, Blakley Benjamin K, Wood Constance S, Wei Yansheng, Showalter Brandon, Dybeck Eric, Remish Emma R, Guidolin Valeria, Bernat Bryan A, McLean John A
Department of Chemistry, Center for Innovative Technology, Vanderbilt University, Nashville, Tennessee 37235, United States.
Pfizer, Inc., Worldwide Research, Development, and Medical, Lake Forest, Illinois 60045, United States.
Anal Chem. 2024 Jul 16;96(30):12453-62. doi: 10.1021/acs.analchem.4c02056.
Structural mass spectrometry (MS) techniques are fast and sensitive analytical methods to identify noncovalent guest/host complexation phenomena for desirable solution-phase properties. Current MS-based studies on guest/host complexes of drug and drug-like molecules are sparse, and there is limited guidance on how to interpret MS information in the context of host nanoencapsulation and inclusion. Here, we use structural MS strategies, combining energy-resolved MS (ERMS), ion mobility-MS (IM-MS), and computational modeling, to characterize 14 chemically distinct drug and drug-like compounds for their propensity to form guest/host complexes with the widely used excipient, beta-cyclodextrin (βCD). The majority (11/14) yielded a 1:1 guest/host complex, and ion mobility collision cross section (CCS) analysis provided subtle evidence of gas-phase compaction of complexes in both polarities. The three distinct dissociation channels observed in ERMS (i.e., charged βCD, charged guest, and partial guest loss) were used to direct charge-site assignments for computational modeling, and structural candidates were prioritized using helium-derived CCS measurements combined with root-mean-square distance analysis. The combined analytical information from ERMS, IM-MS, and computational modeling suggested that the majority of anhydrous complexes are inclusion complexes with βCD. Taken together, this work demonstrates a roadmap for how multiple MS-based analytical measurements can be combined to interpret the structures that guest/host complexes adopt in the absence of water.
结构质谱(MS)技术是用于识别非共价客体/主体络合现象以获得理想溶液相性质的快速且灵敏的分析方法。目前基于MS对药物及类药物分子的客体/主体络合物的研究较少,并且在宿主纳米包封和包合的背景下如何解释MS信息方面的指导有限。在此,我们使用结构MS策略,结合能量分辨质谱(ERMS)、离子淌度质谱(IM-MS)和计算建模,来表征14种化学性质不同的药物及类药物化合物与广泛使用的辅料β-环糊精(βCD)形成客体/主体络合物的倾向。大多数(11/14)形成了1:1的客体/主体络合物,离子淌度碰撞截面(CCS)分析提供了两种极性下络合物气相压缩的细微证据。在ERMS中观察到的三个不同的解离通道(即带电荷的βCD、带电荷的客体和部分客体损失)用于指导计算建模的电荷位点分配,并使用氦衍生的CCS测量结合均方根距离分析对结构候选物进行优先级排序。来自ERMS、IM-MS和计算建模的综合分析信息表明,大多数无水络合物是与βCD形成的包合物。综上所述,这项工作展示了一条路线图,说明如何将多种基于MS的分析测量方法结合起来,以解释在无水情况下客体/主体络合物所采用的结构。